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Which postmenopausal
women should be offered
combined HRT?
■ EVIDENCE-BASED ANSWER
Recent studies have demonstrated a small butsignificant risk of adverse effects from com-
bined hormone replacement therapy (HRT),
including cardiovascular disease, thromboembol-
ic disease, and breast cancer. Time-limited HRT
will control intolerable menopausal symptoms
and prevent risk of fractures in newly
menopausal women. However, HRT achieves its
maximum efficacy in 35 years, and the risk of
adverse outcomes increases as time progresses.
Women considering HRT, particularly those at
higher risk for vascular disease and breast can-
cer, should be informed of the potential risks.
There is inadequate evidence to determine the
extent of these risks in women who have had a
hysterectomy and are taking unopposed estrogen
(strength of recommendation: A, based on large
randomized controlled trials).
■ EVIDENCE SUMMARY
The Women’s Health Initiative (WHI),1 the
largest randomized trial of HRT, showed that
long-term use of HRT poses more risks than ben-
efits for healthy postmenopausal women. WHI
studied the use of estrogen plus progestin for
prevention of coronary heart disease in 16,608
postmenopausal women age 50–79 years. After 
5 years of follow-up, this arm of the study was
stopped because of the adverse effects of the
intervention. The researchers found that HRT
increases the risk of several events:
• coronary heart disease events (number needed
to harm [NNH]=1428)
• invasive breast cancer (NNH=1250)
• stroke (NNH=1250)
• venous thromboembolic events
(NNH=555)
• pulmonary embolism (NNH=1250).
An ongoing arm of WHI is studying estrogen
alone in postmenopausal women who have had a
hysterectomy.
The Heart and Estrogen/progestin Replacement
Study (HERS)2 examined the effects of HRT in post-
menopausal women with coronary artery disease.
HERS was a large randomized controlled trial of
2763 women with an average follow-up time of 4.1
years. It showed no statistically significant differ-
ence between the HRT (estrogen plus medroxyprog-
esterone) group compared with the placebo group in
either the primary outcomes (nonfatal myocardial
infarction or coronary heart disease death) or in the
secondary outcomes (coronary revascularization,
unstable angina, congestive heart failure, resuscitat-
ed cardiac arrest, stroke or transient ischemic
attack, and peripheral arterial disease). The findings
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Clinical  Inquiries
What is a Clinical Inquiry?
Clinical Inquiries answer real questions that family
physicians submit to the Family Practice Inquiries
Network (FPIN), a national, not-for-profit consor-
tium of family practice departments, residency
programs, academic health sciences libraries,
primary care practice-based research networks,
and individuals with particular expertise.
Questions chosen for Clinical Inquiries are
those considered most important, according to
results of web-based voting by family physicians
across the U.S.
Answers are developed by a specific
method:
• First, extensive literature searches are con-
ducted by medical librarians.
• Clinicians then review the evidence and write
the answers, which are then peer reviewed.
• Finally, a practicing family physician writes a
commentary.
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of the WHI and HERS trials have been summarized
in a recent meta-analysis done for the United States
Preventive Services Task Force.3
Both the WHI and HERS trials demonstrated
some benefits for HRT. WHI found a reduced risk of
colorectal cancer (number needed to treat
[NNT]=1667) and a decreased risk of any osteo-
porotic fracture (NNT=228). The HERS group
found that HRT improved the quality of life 
of women with postmenopausal symptoms, particu-
larly flushing.
Evidence indicates that women who take HRT for
3 years and then stop achieve as much protection
from osteoporotic fractures as women who continue
their HRT beyond 3 years.4
Continuing HRT beyond 5 years dramatically
increases the risk of coronary heart disease, 
stroke, thromboembolic events, breast cancer, and 
cholecystitis.3
■ RECOMMENDATIONS FROM OTHERS
The American College of Obstetricians and
Gynecologists has convened a multispecialty
panel of experts to draft new recommendations
for HRT in light of the WHI findings.
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■ CLINICAL COMMENTARY
The WHI and HERS trials demonstrated that long-
term use of HRT (>5 years) incurs significantly
more risks than benefits for a postmenopausal
woman who has not undergone hysterectomy.
However, these trials did not evaluate post-
menopausal symptoms or quality of life as primary
endpoints.
Most women experience postmenopausal symp-
toms for more than 1 year but have resolution of
symptoms within a few years after menopause.
Since HRT remains the most effective therapy for
hot flushes, short-term use of HRT (<5 years) may
be offered to women experiencing postmenopausal
symptoms.
Physicians may instruct women to attempt HRT
discontinuation each year because the duration of
symptoms can be variable. Discontinuation should
be performed using gradual dose reductions to pre-
vent rapid return of postmenopausal symptoms. 
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Is pneumococcal vaccine
effective in nursing home
patients?
■ EVIDENCE-BASED ANSWER
Evidence from clinical trials supports the useof pneumococcal polysaccharide vaccine for
prevention of pneumonia in nursing home
patients (strength of recommendation: B, based
on randomized, nonblinded clinical trials).
Case-control studies have consistently shown
the efficacy of pneumococcal vaccine in preventing
invasive pneumococcal disease and bacteremia for
